Certain Breast Cancer Patients Can Safely Forgo Axillary Surgery
Breast cancer patients without axillary lymph node involvement who have tumors no larger than 2 cm can safely forgo axillary surgery, a phase 3 trial suggests.
Breast cancer patients without axillary lymph node involvement who have tumors no larger than 2 cm can safely forgo axillary surgery, a phase 3 trial suggests.
Adding HIPEC to interval cytoreductive surgery improves long-term outcomes in stage III epithelial ovarian cancer, a phase 3 trial suggests.
First-line treatment with dabrafenib and trametinib can improve outcomes, when compared to standard chemotherapy, in children with BRAFV600-mutated low-grade glioma, a phase 2 trial suggests.
Researchers say they have detected breast cancer in ctDNA from breast milk, and breast milk may allow for earlier cancer detection than plasma.
Long-term historical exposure to air pollution is associated with an increased risk of breast cancer, a new study suggests.
Data suggest that many patients with HER2+, metastatic colorectal cancer do not receive HER2-targeted therapy as recommended by NCCN guidelines.
Cancer deaths increased during the first 2 years of the COVID-19 pandemic in the United States, a population-based study suggests.
Taking adjuvant endocrine therapy for 7 to 8 years is likely sufficient for maximal disease-free survival benefits among most postmenopausal women with HR+ breast cancer, according to researchers.
A genetic testing station can increase uptake and improve the efficiency of genetic testing for patients with ovarian cancer, a study suggests.
Adding ipilimumab to treatment with nivolumab does not provide a clinically meaningful benefit in patients with certain cancers, a meta-analysis suggests.